Early Disturbance of Lymphatic Transport as a Risk Factor for the Development of Breast-Cancer-Related Lymphedema.
ICG lymphofluoroscopy
early detection
lymphedema
near-infrared fluorescence
risk
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Mar 2023
15 Mar 2023
Historique:
received:
31
01
2023
revised:
01
03
2023
accepted:
11
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Breast-cancer-related lymphedema (BCRL) is a frequently occurring and debilitating condition. When lymphedema is diagnosed late, treatment can be expected to be less effective. Lymphofluoroscopy can provide details about the superficial lymphatic architecture and can detect an early disturbance of lymphatic transport (i.e., dermal backflow) before the lymphedema is clinically visible. The main objective of this study is to investigate whether this early disturbance of lymphatic transport visualized by lymphofluoroscopy is a risk factor for the development of BCRL. All patients scheduled for unilateral breast cancer surgery with axillary lymph node dissection or sentinel node biopsy were considered. Patients were assessed at baseline and 1, 3, 6, 9, 12, 18, 24 and 36 months postoperatively. During each visit, a clinical assessment was performed to determine the volume difference between both arms and hands (through circumference measurements and water displacement). Clinical BCRL was defined as a ≥5% increase in relative arm volume difference compared to the baseline value. Variables related to (1) the disturbance of lymphatic transport (through lymphofluoroscopy), (2) the demographics and general health of the patient and (3) the breast cancer and treatment of the patient were collected. We included data of 118 patients in the present study. Thirty-eight patients (39.8%) developed BCRL. Early disturbance of lymphatic transport was identified as a risk factor for the development of clinical BCRL (HR 2.808). Breast-cancer- and treatment-related variables such as axillary lymph node dissection (ALND) (HR 15.127), tumor stage (HR 1.745), mastectomy (HR 0.186), number of positive lymph nodes (HR 1.121), number of removed lymph nodes (HR 1.055), radiotherapy of the axilla (HR 2.715), adjuvant taxanes (HR 3.220) and postsurgical complications (HR 2.590) were identified as significant risk factors for the development of BCRL. In the multivariate analysis, age and ALND were withheld as independent risk factors for the development of BCRL. Lymphofluoroscopy can identify an early disturbance of lymphatic transport after breast cancer treatment. Patients with an early disturbance of lymphatic transport are considered to be a high-risk group for the development of BCRL. This study also confirms that age and ALND are predictors for the development of BCRL. Therefore, a surveillance program of these patients with lymphofluoroscopy could be useful to identify lymphedema in subclinical stages.
Identifiants
pubmed: 36980660
pii: cancers15061774
doi: 10.3390/cancers15061774
pmc: PMC10046360
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Clinical Research Fund of the University Hospitals Leuven
ID : KOOR 2017, S60382.
Références
Lymphat Res Biol. 2019 Jun;17(3):368-373
pubmed: 30543479
Am J Surg. 2004 Jan;187(1):69-72
pubmed: 14706589
Clin Breast Cancer. 2022 Jan;22(1):e37-e47
pubmed: 34376347
Lymphat Res Biol. 2014 Dec;12(4):289-94
pubmed: 25495384
Ann Surg Oncol. 2009 Jul;16(7):1959-72
pubmed: 19365624
Psychooncology. 2008 Nov;17(11):1108-20
pubmed: 18314912
Breast. 2015 Oct;24(5):543-7
pubmed: 26051795
Phys Ther. 2006 Feb;86(2):205-14
pubmed: 16445334
Breast Cancer. 2010 Oct;17(4):281-5
pubmed: 19789952
Breast Cancer Res Treat. 2022 Aug;195(1):33-41
pubmed: 35816269
Lymphat Res Biol. 2015 Dec;13(4):268-74
pubmed: 24837643
Int J Breast Cancer. 2013;2013:641818
pubmed: 23862068
Int Angiol. 2010 Oct;29(5):401-7
pubmed: 20924341
Breast Cancer Res Treat. 2015 Jun;151(2):393-403
pubmed: 25940996
Ann Surg Oncol. 2013 Mar;20(3):842-9
pubmed: 23054109
Cancer Med. 2016 Jun;5(6):1154-62
pubmed: 26993371
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
J Clin Oncol. 2002 Oct 15;20(20):4242-8
pubmed: 12377968
Breast Cancer. 2020 Sep;27(5):929-937
pubmed: 32270417
Diagnostics (Basel). 2022 Apr 14;12(4):
pubmed: 35454031
J Surg Oncol. 2010 Aug 1;102(2):111-8
pubmed: 20648579
Lymphat Res Biol. 2013 Jun;11(2):66-71
pubmed: 23772715
J Appl Physiol (1985). 2007 Sep;103(3):917-25
pubmed: 17585046
Gland Surg. 2018 Aug;7(4):379-403
pubmed: 30175055
J Obes. 2016;2016:8241710
pubmed: 27433356
Breast Cancer Res Treat. 2006 Oct;99(3):267-73
pubmed: 16752072
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Lymphology. 2020;53(1):3-19
pubmed: 32521126
Lymphat Res Biol. 2013 Jun;11(2):72-5
pubmed: 23772716
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):71-78
pubmed: 30102206
J Clin Oncol. 2016 Mar 1;34(7):691-8
pubmed: 26644530
Plast Reconstr Surg. 2011 Oct;128(4):941-947
pubmed: 21681123
Breast Care (Basel). 2018 Oct;13(5):380-385
pubmed: 30498426
Indian J Plast Surg. 2022 Feb 25;55(1):18-25
pubmed: 35444756
PLoS One. 2012;7(6):e38182
pubmed: 22675520
Lymphat Res Biol. 2020 Apr;18(2):116-128
pubmed: 31329510
J Plast Reconstr Aesthet Surg. 2013 Jun;66(6):792-8
pubmed: 23523168
Arch Surg. 2010 Nov;145(11):1055-63
pubmed: 21079093
Plast Reconstr Surg. 2013 Feb;131(2):283-290
pubmed: 23357989
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810570
Breast Cancer Res Treat. 2009 Jan;113(2):383-91
pubmed: 18297429
Cochrane Database Syst Rev. 2019 Feb 19;2:CD011433
pubmed: 30779124
Plast Reconstr Surg. 2016 Aug;138(2):192e-202e
pubmed: 27465179
J Clin Oncol. 2006 Jun 20;24(18):2765-72
pubmed: 16702582
BMJ Open. 2020 Dec 4;10(12):e042018
pubmed: 33277289
Cancer Radiother. 2012 Apr;16(2):123-7
pubmed: 22342349
Br J Surg. 2015 Aug;102(9):1071-8
pubmed: 26040263
J Cancer Surviv. 2015 Sep;9(3):422-30
pubmed: 25913877
Front Oncol. 2020 Jul 17;10:1061
pubmed: 32766138